drugset / Trial / NCT01369511

A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement

NCT01369511

Phase 2 Completed 400 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip arthroplasty (eTHA).

Timeline

Start
2011-07
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject LANDOGROZUMAB Monoclonal antibody 35 mg Subcutaneous
Subject LANDOGROZUMAB Monoclonal antibody 105 mg Subcutaneous
Subject LANDOGROZUMAB Monoclonal antibody 315 mg Subcutaneous

Indications